Geron Corp. (NASDAQ:GERN)‘s stock had its “neutral” rating restated by investment analysts at BTIG Research in a research note issued to investors on Tuesday.

Several other research firms have also issued reports on GERN. Zacks Investment Research raised shares of Geron Corp. from a “hold” rating to a “strong-buy” rating and set a $3.00 price target on the stock in a research report on Friday, August 5th. FBR & Co dropped their price objective on shares of Geron Corp. from $6.00 to $5.00 and set an “outperform” rating on the stock in a research report on Tuesday, September 13th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and issued a $5.00 price objective (down from $10.00) on shares of Geron Corp. in a research report on Tuesday, September 13th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Geron Corp. presently has a consensus rating of “Buy” and an average price target of $5.00.

Shares of Geron Corp. (NASDAQ:GERN) traded up 4.50% during mid-day trading on Tuesday, hitting $2.09. 1,211,719 shares of the stock traded hands. The firm has a market capitalization of $332.60 million, a P/E ratio of 261.25 and a beta of 2.63. The company’s 50 day moving average is $2.64 and its 200 day moving average is $2.80. Geron Corp. has a one year low of $1.84 and a one year high of $5.30.

Geron Corp. (NASDAQ:GERN) last posted its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.07) by $0.02. Geron Corp. had a net margin of 3.39% and a return on equity of 0.89%. The firm had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.38 million. During the same period in the prior year, the firm posted ($0.06) earnings per share. The company’s quarterly revenue was down 15.9% compared to the same quarter last year. On average, equities analysts expect that Geron Corp. will post ($0.23) EPS for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in GERN. Bank of Montreal Can acquired a new position in Geron Corp. during the second quarter valued at approximately $108,000. Creative Planning increased its position in Geron Corp. by 3.5% in the second quarter. Creative Planning now owns 59,700 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 2,000 shares during the period. Panagora Asset Management Inc. increased its position in Geron Corp. by 32.9% in the first quarter. Panagora Asset Management Inc. now owns 1,823,587 shares of the biopharmaceutical company’s stock valued at $5,325,000 after buying an additional 451,440 shares during the period. LPL Financial LLC increased its position in Geron Corp. by 81.0% in the first quarter. LPL Financial LLC now owns 35,750 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 16,000 shares during the period. Finally, Metropolitan Life Insurance Co. NY increased its position in Geron Corp. by 0.7% in the first quarter. Metropolitan Life Insurance Co. NY now owns 113,715 shares of the biopharmaceutical company’s stock valued at $332,000 after buying an additional 839 shares during the period. Institutional investors and hedge funds own 38.09% of the company’s stock.

Geron Corp. Company Profile

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company operates through the segment, which includes discovery and development of therapeutic products for oncology.

5 Day Chart for NASDAQ:GERN

Receive News & Ratings for Geron Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.